**SUPPLEMENTARY MATERIAL**

**Appendix A: Email Script**

Greetings,

I lead a group at Texas A&M University and University of Nebraska Medical Center that does consulting for hospitals and other organizations that are setting up laboratory capabilities to treat patients with highly infectious diseases. I’ve attached a link to our profiles and three related papers if you would like a greater understanding of our work.

·       <https://public-health.tamu.edu/dean/index.html>

·       <https://orcid.org/0000-0002-6041-5166>

·       <https://www.unmc.edu/healthsecurity/>

·       https://[www.ncbi.nlm.nih.gov/pubmed/26842705](http://www.ncbi.nlm.nih.gov/pubmed/26842705)

·       https://[www.ncbi.nlm.nih.gov/pubmed/25511134](http://www.ncbi.nlm.nih.gov/pubmed/25511134)

·       <https://pubmed.ncbi.nlm.nih.gov/31216938/>

We are gathering information from companies that manufacture/service laboratory equipment on their policies as they relate to equipment used on samples from patients with confirmed highly infectious diseases (e.g., Ebola virus, smallpox, Middle East Respiratory syndrome (MERS)-coronavirus). This information will be used in providing instruction to facilities setting up laboratories, and for peer-reviewed publication. This is a repeat of the third paper above and the study we did several years ago.

As a leading manufacturer of laboratory devices and equipment, we highly value the information you can provide. We hope you are willing to complete the attached document on your company’s policies regarding use of equipment or devices on 26 specific pathogens, or forward to the appropriate person(s). The document should take between 5-10 minutes to complete.

Please complete and return the attached document to me by **DATE**. If you are not the correct person to complete this request, then please let us know who we should contact at your organization. I am happy to answer any questions you may have.

For the following, please select whether use of laboratory equipment or devices manufactured and serviced by your company on a patient confirmed to be infected with the listed agent would void the warranty or result in cancellation of service contracts. Additional space is provided to describe company policy and provide further information

**Appendix B. List of pathogens inquired about with CLE manufacturers**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Disease | Void warranty | Cancel service contracts | Recommendations for Laboratories |  | Policy Description/Additional Information |
| Anthrax |[ ] [ ]   |  |  |
| Avian Influenza |[ ] [ ]   |  |  |
| Botulism |[ ] [ ]   |  |  |
| Crimean-Congo hemorrhagic fever |[ ] [ ]   |  |  |
| Ebola virus disease (EVD) |[ ] [ ]   |  |  |
| Extensively drug-resistant tuberculosis (XDR-TB) |[ ] [ ]   |  |  |
| Guanarito virus disease |[ ] [ ]   |  |  |
| Junin virus disease |[ ] [ ]   |  |  |
| Kyasanur Forest disease |[ ] [ ]   |  |  |
| Lassa fever |[ ] [ ]   |  |  |
| Machupo virus disease |[ ] [ ]   |  |  |
| Marburg fever |[ ] [ ]   |  |  |
| Middle East respiratory syndrome (MERS) |[ ] [ ]   |  |  |
| Monkeypox |[ ] [ ]   |  |  |
| Nipah virus disease |[ ] [ ]   |  |  |
| Omsk hemorrhagic fever |[ ] [ ]   |  |  |
| Pneumonic Plague |[ ] [ ]   |  |  |
| Q fever |[ ] [ ]   |  |  |
| Rift Valley fever |[ ] [ ]   |  |  |
| Sabia virus disease |[ ] [ ]   |  |  |
| Severe acute respiratory syndrome (SARS) |[ ] [ ]   |  |  |
| Smallpox |[ ] [ ]   |  |  |
| Staphylococcal enterotoxigenic B (SEB)-caused disease |[ ] [ ]   |  |  |
| Tularemia |[ ] [ ]   |  |  |
| “Unknown” emerging infectious disease |[ ] [ ]   |  |  |
| Venezuelan equine encephalitis |[ ] [ ]   |  |  |

**Note:** Since our 2019 inquiry(4), we have added Crimean-Congo hemorrhagic fever, Kyasanur Forest disease, Marburg fever, Nipah virus disease, Omsk hemorrhagic fever, Rift Valley fever, and Venezuelan equine encephalitis to the list given its global emergence and/or re-emergence.